Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women.
What this study found
Adding ergocalciferol to calcium reduced falls in this population. At least 1 fall during 1 year occurred in 53.0% of the ergocalciferol group versus 62.9% of controls, with OR 0.61 and 95% CI 0.37-0.99; the adjusted RR was 0.61. Benefit was clearest for first falls in winter or spring, where 25.2% versus 35.8% fell, OR 0.55 (95% CI 0.32-0.96), RR 0.77 (95% CI 0.56-0.98), while summer or autumn showed no clear effect (OR 0.81; 95% CI 0.46-1.42). The intervention also reduced having 1 fall (21.2% vs 33.8%; OR 0.50; 95% CI 0.28-0.88), but not more than 1 fall (OR 0.66; 95% CI 0.41-1.06). No…
- Study & population
- Randomized, placebo-controlled trial in ambulatory, community-dwelling women aged 70 to 90 years in Perth, Australia.
- Intervention
- The active regimen was ergocalciferol 1000 IU/day added to calcium citrate 1000 mg/day for 1 year.
- Key limitation
- The trial was limited to elderly women with prior falls and vitamin D insufficiency in Perth, Australia, so generalizability is narrow.
Original abstract
BACKGROUND Ergocalciferol (vitamin D(2)) supplementation plays a role in fall prevention, but the effect in patients living in the community in sunny climates remains uncertain. We evaluated the effect of ergocalciferol and calcium citrate supplementation compared with calcium alone on the risk of falls in older women at high risk of falling. METHODS A 1-year population-based, double-blind, randomized controlled trial of 302 community-dwelling ambulant older women aged 70 to 90 years living in Perth, Australia (latitude, 32 degrees S), with a serum 25-hydroxyvitamin D concentration of less than 24.0 ng/mL and a history of falling in the previous year. Participants were randomized to receive ergocalciferol, 1000 IU/d, or identical placebo (hereinafter, ergocalciferol and control groups, respectively). Both groups received calcium citrate, 1000 mg/d. Fall data were collected every 6 weeks. RESULTS Ergocalciferol therapy reduced the risk of having at least 1 fall over 1 year after adjustment for baseline height, which was significantly different between the 2 groups (ergocalciferol group, 53.0%; control group, 62.9%; odds ratio [OR], 0.61; 95% confidence interval [CI], 0.37-0.99). When those who fell were grouped by the season of first fall or the number of falls they had, ergocalciferol treatment reduced the risk of having the first fall in winter and spring (ergocalciferol group, 25.2%; control group, 35.8%; OR, 0.55; 95% CI, 0.32-0.96) but not in summer and autumn, and reduced the risk of having 1 fall (ergocalciferol group, 21.2%; control group, 33.8%; OR, 0.50; 95% CI, 0.28-0.88) but not multiple falls. CONCLUSION Patients with a history of falling and vitamin D insufficiency living in sunny climates benefit from ergocalciferol supplementation in addition to calcium, which is associated with a 19% reduction in the relative risk of falling, mostly in winter.